Mini review: genome and transcriptome editing using CRISPR-cas systems for haematological malignancy gene therapy

No abstract is available for this paper.

• Publication year

  2021

• Venue

  Transgenic research

• Publication date

  2021-02-20

• Fields of study

  Medicine

• Identifiers
  DOI 10.1007/s11248-020-00232-9PMID 33609253
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• CRISPR-engineered T cells in patients with refractory cancer

  2020cited by this paper
• CRISPR to fix bad blood: a new tool in basic and clinical hematology

  2019cited by this paper
• Search-and-replace genome editing without double-strand breaks or donor DNA

  2019cited by this paper
• Hematopoietic Stem Cell Transplant for the Treatment of X-MAID

  2019cited by this paper
• Improving homology-directed repair efficiency in human stem cells.

  2019cited by this paper
• Transcriptome Engineering with RNA-Targeting Type VI-D CRISPR Effectors.

  2018cited by this paper
• Identification of preexisting adaptive immunity to Cas9 proteins in humans

  2018cited by this paper
• Priming Human Repopulating Hematopoietic Stem and Progenitor Cells for Cas9/sgRNA Gene Targeting

  2018cited by this paper
• CRISPR base editors: genome editing without double-stranded breaks

  2018cited by this paper
• Genetic Landscape of Acute Myeloid Leukemia Interrogated by Next-generation Sequencing: A Large Cancer Center Experience.

  2018cited by this paper
• CRISPR-mediated TCR replacement generates superior anticancer transgenic T cells.

  2018cited by this paper
• Genetics of diffuse large B-cell lymphoma.

  2018cited by this paper
• Activating PTEN Tumor Suppressor Expression with the CRISPR/dCas9 System

  2018cited by this paper
• Development of an integrated CRISPRi targeting ΔNp63 for treatment of squamous cell carcinoma

  2018cited by this paper
• CRISPR/Cas9 genome editing: Fueling the revolution in cancer immunotherapy.

  2018cited by this paper
• Multiplexed and portable nucleic acid detection platform with Cas13, Cas12a, and Csm6

  2018cited by this paper
• Field-deployable viral diagnostics using CRISPR-Cas13

  2018cited by this paper
• Applications and advances of CRISPR-Cas9 in cancer immunotherapy

  2018cited by this paper
• Exome Sequencing Diagnoses X-Linked Moesin-Associated Immunodeficiency in a Primary Immunodeficiency Case

  2018cited by this paper
• Immunity to CRISPR Cas9 and Cas12a therapeutics

  2018influential reference
• An ‘off-the-shelf’ fratricide-resistant CAR-T for the treatment of T cell hematologic malignancies

  2018cited by this paper
• RNA targeting with CRISPR–Cas13

  2017cited by this paper
• The Molecular Architecture for RNA-Guided RNA Cleavage by Cas13a.

  2017cited by this paper
• RNA Targeting by Functionally Orthogonal Type VI-A CRISPR-Cas Enzymes.

  2017cited by this paper
• CRISPR-Cas9-mediated disruption of PD-1 on human T cells for adoptive cellular therapies of EBV positive gastric cancer

  2017cited by this paper
• Advances in the delivery of RNA therapeutics: from concept to clinical reality

  2017cited by this paper
• Cancer‐specific mortality, cure fraction, and noncancer causes of death among diffuse large B‐cell lymphoma patients in the immunochemotherapy era

  2017cited by this paper
• RNA editing with CRISPR-Cas13

  2017cited by this paper
• Ethical and regulatory aspects of genome editing.

  2016cited by this paper
• Multiplex Genome Editing to Generate Universal CAR T Cells Resistant to PD1 Inhibition

  2016cited by this paper
• An efficient system for selectively altering genetic information within mRNAs

  2016cited by this paper
• Programmable RNA Tracking in Live Cells with CRISPR/Cas9.

  2016cited by this paper
• X-linked primary immunodeficiency associated with hemizygous mutations in the moesin (MSN) gene.

  2016cited by this paper
• C2c2 is a single-component programmable RNA-guided RNA-targeting CRISPR effector

  2016influential reference
• Genomic Classification and Prognosis in Acute Myeloid Leukemia.

  2016cited by this paper
• Potential pitfalls of CRISPR/Cas9‐mediated genome editing

  2016cited by this paper
• Programmable editing of a target base in genomic DNA without double-stranded DNA cleavage

  2016cited by this paper
• DNase H Activity of Neisseria meningitidis Cas9.

  2015cited by this paper
• Genome editing: the end of the beginning

  2015cited by this paper
• Applications of Cas9 as an RNA-programmed RNA-binding protein.

  2015cited by this paper
• Applications of Cas 9 as an RNA-programmed RNA-binding protein

  2015cited by this paper
• Genome engineering using CRISPR-Cas9 system.

  2015cited by this paper
• Resource Engineering Complex Synthetic Transcriptional Programs with CRISPR RNA Scaffolds

  2015cited by this paper
• The new frontier of genome engineering with CRISPR-Cas9

  2014influential reference
• Efficient genome modification by CRISPR-Cas9 nickase with minimal off-target effects

  2014cited by this paper
• Programmable RNA recognition and cleavage by CRISPR/Cas9

  2014cited by this paper
• CRISPR/Cas9 for genome editing: progress, implications and challenges.

  2014cited by this paper
• Enhanced homology-directed human genome engineering by controlled timing of CRISPR/Cas9 delivery

  2014cited by this paper
• Genome engineering using the CRISPR-Cas9 system

  2013cited by this paper
• Multiplex Genome Engineering Using CRISPR/Cas Systems

  2013cited by this paper
• CRISPR-Cas systems target a diverse collection of invasive mobile genetic elements in human microbiomes

  2013cited by this paper
• RNA-dependent DNA endonuclease Cas9 of the CRISPR system: Holy Grail of genome editing?

  2013cited by this paper
• Multiplexed activation of endogenous genes by CRISPR-on, an RNA-guided transcriptional activator system

  2013cited by this paper
• A Programmable Dual-RNA–Guided DNA Endonuclease in Adaptive Bacterial Immunity

  2012cited by this paper
• Cas9–crRNA ribonucleoprotein complex mediates specific DNA cleavage for adaptive immunity in bacteria

  2012cited by this paper
• [The efficacy and safety of second allogeneic hematopoietic stem cell transplantation for post-transplant hematologic malignancies relapse].

  2011cited by this paper
• CRISPR-Cas systems in bacteria and archaea: versatile small RNAs for adaptive defense and regulation.

  2011cited by this paper
• WITHDRAWN: Gene silencing by double-stranded RNA

  2007cited by this paper
• Gene silencing by double-stranded RNA.

  2007cited by this paper
• RNA interference is mediated by 21- and 22-nucleotide RNAs.

  2001cited by this paper
• Potent and specific genetic interference by double-stranded RNA in Caenorhabditis elegans

  1998cited by this paper
• Cardiologists send up a trial balloon in new efforts to relieve heart failure.

  1987cited by this paper
• The applications of tongue flaps in head and neck surgery.

  1986cited by this paper
• Serum and cell-mediated viral-specific delayed cutaneous basophil reactions during cytomegalovirus infection of guinea pigs.

  1982cited by this paper
• [Study of the mechanism of ultraviolet inactivation of enzymes. Photolysis of amino acid residues in enzymes (pepsin and trypsin) by ultraviolet irradiation].

  1968cited by this paper

• Utilization of CRISPR-Mediated Tools for Studying Functional Genomics in Hematological Malignancies: An Overview on the Current Perspectives, Challenges, and Clinical Implications

  2022cites this paper
• CRISPR-Cas systems target endogenous genes to impact bacterial physiology and alter mammalian immune responses

  2022cites this paper
• CRISPR-Cas13 technology portfolio and alliance with other genetic tools.

  2022cites this paper